Literature DB >> 23601050

Brain and retinal microglia in health and disease: an unrecognized target of the renin-angiotensin system.

Claudia A McCarthy1, Robert E Widdop, Devy Deliyanti, Jennifer L Wilkinson-Berka.   

Abstract

Microglia are the resident immune cells within the brain and retina, commonly known as the macrophages of the central nervous system (CNS). Microglia survey the surrounding milieu to eliminate invading microbes, clear cellular debris and enforce programmed cell death by removing apoptotic cells. Complementary to their 'house-keeping' role, microglia are capable of releasing brain-derived neurotrophic factor (BDNF), as well as various anti-inflammatory cytokines that sustain and support neuronal survival. Although microglia are essential for maintaining a healthy CNS, paradoxically they may undergo phenotypic changes to influence numerous neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease. Understanding the underlying mechanisms that determine whether microglia are supportive or toxic could elucidate novel and more effective therapeutic targets to treat an array of neurological and retinal diseases. Although relatively little is known about the influences that evoke phenotypic changes in the microglial population, there is accumulating evidence illustrating an interaction with the renin-angiotensin system (RAS). The angiotensin AT1 and AT2 receptors may have differential roles in mediating the activity of microglia. Understanding the actions of these angiotensin receptors will be important in defining whether microglia are an important therapeutic target for RAS blockade in brain and ocular diseases.
© 2013 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  angiotensin; angiotensin AT2 receptor; brain; microglia; retina

Mesh:

Year:  2013        PMID: 23601050     DOI: 10.1111/1440-1681.12099

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  10 in total

1.  Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury.

Authors:  Abdelrahman Y Fouda; Bindu Pillai; Krishnan M Dhandapani; Adviye Ergul; Susan C Fagan
Journal:  Eur J Pharmacol       Date:  2017-02-10       Impact factor: 4.432

Review 2.  The protective arms of the renin-angiontensin system in stroke.

Authors:  Claudia A McCarthy; Lachlan J Facey; Robert E Widdop
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

3.  Isolation of photoreceptors from mature, developing, and regenerated zebrafish retinas, and of microglia/macrophages from regenerating zebrafish retinas.

Authors:  Chi Sun; Diana M Mitchell; Deborah L Stenkamp
Journal:  Exp Eye Res       Date:  2018-08-08       Impact factor: 3.467

Review 4.  Volume Transmission in Central Dopamine and Noradrenaline Neurons and Its Astroglial Targets.

Authors:  Kjell Fuxe; Luigi F Agnati; Manuela Marcoli; Dasiel O Borroto-Escuela
Journal:  Neurochem Res       Date:  2015-04-17       Impact factor: 3.996

5.  Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells.

Authors:  Siva P Kambhampati; Manoj K Mishra; Panagiotis Mastorakos; Yumin Oh; Gerard A Lutty; Rangaramanujam M Kannan
Journal:  Eur J Pharm Biopharm       Date:  2015-02-19       Impact factor: 5.571

6.  Systemic and Intravitreal Delivery of Dendrimers to Activated Microglia/Macrophage in Ischemia/Reperfusion Mouse Retina.

Authors:  Siva P Kambhampati; Alexander J M Clunies-Ross; Imran Bhutto; Manoj K Mishra; Malia Edwards; D Scott McLeod; Rangaramanujam M Kannan; Gerard Lutty
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-07       Impact factor: 4.799

7.  Transcriptomic Analysis of Mouse Brain After Traumatic Brain Injury Reveals That the Angiotensin Receptor Blocker Candesartan Acts Through Novel Pathways.

Authors:  Peter J Attilio; Dustin M Snapper; Milan Rusnak; Akira Isaac; Anthony R Soltis; Matthew D Wilkerson; Clifton L Dalgard; Aviva J Symes
Journal:  Front Neurosci       Date:  2021-03-22       Impact factor: 4.677

8.  FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy.

Authors:  Devy Deliyanti; Yuan Zhang; Fay Khong; David R Berka; David I Stapleton; Darren J Kelly; Jennifer L Wilkinson-Berka
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

9.  Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina.

Authors:  Devy Deliyanti; Jennifer L Wilkinson-Berka
Journal:  J Neuroinflammation       Date:  2015-07-30       Impact factor: 8.322

10.  Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes.

Authors:  Harumasa Yokota; Hiroki Hayashi; Junya Hanaguri; Satoru Yamagami; Akifumi Kushiyama; Hironori Nakagami; Taiji Nagaoka
Journal:  PLoS One       Date:  2022-01-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.